Your Yourlocation: Home > The efficacy of tiotropium bromide(136310-93-5) was superior to ipratropium bromide

Tiotropium bromide(136310-93-5) is a new chemical treatment for COPD, an inhaled anticholinergic agent that is administered once a day for a long-acting bronchodilator effect on airway M3 receptors, the dissociation time of M1 and M3 receptors is 100-fold longer than ipratropium bromide, but the rate of dissociation of M2 is much faster than that of M1 and M3 receptors, so tiotropium bromide(136310-93-5) is a long-acting high-receptor selective inhalation Formulations. In two independent, double-blind, double-dummy trials, Vincken et al included 356 patients with COPD in the tiotropium-treated group (18 μg once daily), and 179 patients with COPD Intravenous ipratropium bromide treatment group (40μg, 4 times a day). The observation time was 1 year. The indicators included: pulmonary function test results, peak expiratory flow rate, sardine the use of amines, dyspnea improvement, health-related quality of life and acute exacerbation of COPD. The results showed that tiotropium bromide can effectively improve the degree of dyspnea in COPD patients, reduce acute exacerbation, improve health-related quality of life and lung function, and the efficacy is better than ipratropium bromide.

So far to prove that effective measures to delay the decline in lung function, only smoking cessation, in addition to smoking cessation, whether from tiotropium bromide(136310-93-5) drug intervention to benefit. To this end, a 4-year UPLIF (UnderstandingthePotentialLong2 TermImpactsonFunctionwithTiotropium) large-scale clinical trials ongoing, to understand whether the long-term treatment of tiotropium effective delay the rate of decline in lung function in patients with COPD, in addition to evaluation of the quality of life of patients. The number of acute exacerbations, hospitalization rate and mortality in patients. The results are worth looking forward to. In a recent one-year clinical trial, it was found that inhaled tiotropium significantly improved lung function and slowed the rate of FEV1 decline. In the long-term treatment study of tiotropium bromide, the most frequently reported adverse events were dry mouth (14%). The dry mouth is usually mild and relieves after continuing treatment, with the prostate gland Hypertrophy of patients should pay attention to the application may increase urinary retention. Tiotropium bromide(136310-93-5) for the treatment of COPD essential drugs, tiotropium bromide replacement of ipratropium bromide as a basic drug for the treatment of COPD in Europe and North America.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved